A Real-world Clinical Study of T-DXd for the Treatment of Chinese Patients With HER2 Overexpressing and HER2 Underexpressing Advanced Breast Cancer

NCT07035353 · clinicaltrials.gov ↗

NOT_YET_RECRUITING

Status

200

Enrollment

OTHER

Sponsor class

Conditions

HER2 Overexpression
Advanced Stage Breast Cancer
Low Expression of HER2

Interventions

DRUG: T-DXd (DS8201) 5.4 mg/kg, IVD, 1 cycle every 21 days.

Sponsor

Tianjin Medical University Cancer Institute and Hospital